Faculty Appointments
Patient Care Settings
Cancer, Radiation Oncology
Biography
It is a privilege to care for our patients. I am committed to providing personalized radiation treatment of the highest quality, as well as compassionate care. My areas of expertise include prostate and head and neck cancers.
Conditions I Treat:
- Prostate cancer
- Head and neck cancers
- Breast cancer
- Other cancers
Credentials
Specialties
- Radiation Oncology - American Board of Radiology
Education
1993
PhD | Case Western Reserve University School of Medicine
2001
MD | Yale New Haven Hospital
Post-doctoral Training & Residency
07/01/2002 - 06/30/2006
Residency in Radiation Oncology at University of Rochester Medical Center
06/01/2001 - 06/01/2002
Internship in Internal Medicine at Rochester General Hospital
06/01/1993 - 12/31/1994
Fellowship in Neuroscience at Case Western Reserve University School of Medicine
VIEW ALL expand_more
Awards
2018
Civic Service Award, Us TOO Rochester
Sponsor: Us TOO Rochester
2017
AAMC Mid-Career Woman Faculty Leadership Development Seminar 12/2017
Sponsor: AAMC
2017
Health Care Achievement Awards--Health Care Innovation
Sponsor: Rochester Business Journal
Location: Rochester, NY
2016
Educator of the Year
Sponsor: Association of Residents in Radiation Oncology
2013
Patient- and Family- Centered ICARE High Performance Award
2012 - 2017
Civic Service Award, Us TOO Rochester
Sponsor: Us TOO Rochester
2012
Educator of the Year
Sponsor: Association of Residents in Radiation Oncology
2012
Patient- and Family-Centered ICARE High Performance Award
Sponsor: University of Rochester Medical Center
2005
Upstate New York Society of Therapeutic Radiology and Oncology Fall Meeting Resident Presenter Award
Location: Syracuse, NY
2005
ASTRO Translational Research in Radiation Oncology Symposium Travel Grant Award
2001
Janet M.Glasgow Memorial Achievement Citations
Sponsor: Yale University School of Medicine
Location: New Haven, Connecticut
2000
Clyde Swift Award for Outstanding Medical Student
Sponsor: Yale University School of Medicine
Location: New Haven, Connecticut
VIEW ALL expand_more
Clinical Trials
Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy
Lead Researcher: Hong Zhang
This phase III trial studies how well adding apalutamide, abiraterone acetate, and prednisone to the usual hormone therapy and radiation therapy works compared to the usual hormone therapy and radiation therapy in treating patients with node-positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or slow the growth of prostate cancer cell growth by blocking the androgens. Abiraterone acetate blocks some of the enzymes needed for androgen production and may cause the death of prostate cancer cells that need androgens to grow. Prednisone may help abiraterone acetate work better by making tumor cells more sensitive to the drug. Adding apalutamide and abiraterone acetate with prednisone to the usual usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading or extend time without disease spreading compared to the usual approach.
View Study Details
RANDOMIZED PHASE II TRIAL OF NIRAPARIB WITH STANDARD COMBINATION RADIOTHERAPY AND ANDROGEN DEPRIVATION THERAPY (ADT) IN HIGH RISK PROSTATE CANCER (WITH INITIAL PHASE I) (NRG-GU007)
Lead Researcher: Hong Zhang
This phase II trial studies the side effects and best dose of niraparib, and to see how well it works in combination with standard of care radiation therapy and hormonal therapy (androgen deprivation therapy) in treating patients with prostate cancer that has a high chance of coming back (high risk). Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding niraparib to the usual treatments of radiation therapy and hormonal therapy may lower the chance of prostate cancer growing or returning.
View Study Details
Publications
Journal Articles
2020
Zhang H, Kang S, Ali N, Baran A, Bylund K, Gentile D, Previte G, Matloubieh A, Gray A, Marou N. "Building a High-Dose-Rate Prostate Brachytherapy Program With Real-Time Ultrasound-Based Planning: Initial Safety, Quality, and Outcome Results." Advances in radiation oncology.. 2020 5(3):388-395. Epub 2020 Feb 21.
2/2019
Milano MT, Katz AW, Zhang H, Huggins CF, Aujla KS, Okunieff P. "Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.. 2019 Feb 0; 131:45-51. Epub 2018 Dec 28.
2019
Hong Zhang, Chris Duecette, Hongmei Young, Sanjukta Bandyopadhyay, Craig Grossman, Jerome Jean Gilles, Edward Messing, Yuhchyau Chen. "Risk of Adverse Pathological Features for Intermediate Risk Prostate Cancer: Clinical Implication for Definitive Radiation Therapy" . International Journal of Clinical Oncology. 2019; .
Books & Chapters
2009
Chapter Title: Breast Cancer
Book Title: Principles and Practice of Radiation Therapy
Author List: Uschold G; Zhang H
Edited By: Washington CM; Leaver D
Published By: Mosby Elsevier 2009
VIEW ALL PUBLICATIONS
Videos
play_circle_filled
Radiation Oncology at Highland Hospital